Tango Therapeutics, Inc. ((TNGX)) announced an update on their ongoing clinical study.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Study Overview: Tango Therapeutics, Inc. is conducting a Phase 1/2 study titled ‘A Phase 1/2, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, and Preliminary Anti-tumor Activity of TNG462 as a Single Agent and in Combination in Patients With MTAP-deleted Advanced or Metastatic Solid Tumors.’ The study aims to assess the safety and effectiveness of TNG462 in treating MTAP-deleted solid tumors, a significant area of unmet medical need.
Intervention/Treatment: The study tests TNG462, a selective PRMT5 inhibitor, administered orally. It is evaluated alone and in combination with pembrolizumab, an anti-PD-1 antibody, to determine its maximum tolerated dose and recommended phase 2 dose.
Study Design: This interventional study is non-randomized with a sequential intervention model. It includes an open-label dose escalation phase followed by a dose expansion phase across five arms, focusing on treatment as the primary purpose without any masking.
Study Timeline: The study began on January 30, 2023, and is currently recruiting. The latest update was submitted on May 5, 2025, indicating ongoing progress and adjustments as necessary.
Market Implications: This study update could positively influence Tango Therapeutics’ stock performance by demonstrating progress in addressing MTAP-deleted tumors. Success in this study may enhance investor confidence and position the company favorably against competitors in the oncology sector.
The study is ongoing, with further details available on the ClinicalTrials portal.